[{"Assets_0_Q3_USD":4580697000.0,"CommonStockSharesOutstanding_0_Q3_shares":175495350.0,"EarningsPerShareBasic_1_Q3_USD":-0.07,"EarningsPerShareBasic_3_Q3_USD":-0.38,"EarningsPerShareDiluted_1_Q3_USD":-0.07,"EarningsPerShareDiluted_3_Q3_USD":-0.38,"NetIncomeLoss_1_Q3_USD":-12527000.0,"NetIncomeLoss_3_Q3_USD":-65650000.0,"StockholdersEquity_0_Q3_USD":2813562000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":175103000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":174071000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":175103000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":174071000.0,"Ticker":"BMRN","CIK":"1048477","name":"BIOMARIN PHARMACEUTICAL INC","OfficialName":"BioMarin Pharmaceutical Inc. Common Stock","form":"10-Q","period":"20170930","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"14899091235.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20171031"}]